Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PACO NET INCOME CLIMBS 20% IN THIRD QUARTER TO $1.2 MIL.; FIRM ENTERS MARKETING PACT WITH "MAJOR" DRUG FIRM FOR PROPRIETARY CONTACT LENS CARE SOLUTIONS

Executive Summary

Paco's net income jumped 20% in the third quarter ended May 9 to $1.2 mil. despite an 11% decline in volume, from $10.7 mil. in the comparable 1986 period to $9.5 mil. For the first nine months of fiscal 1987, the drug packager's sales were flat at approximately $30 mil. Profits for the nine months ended May 9 were up 11% to $3.1 mil. Paco announced the signing of a supply agreement with "a major pharmaceutical company" covering Paco's proprietary contact lens care solutions. "Test marketing will commence during 1987 and the results of the tests will determine the eventual magnitude of the agreement," the company said. Repligen attributed an $18.1 mil. fourth quarter loss to a nonrecurring charge for the acquisition of technologies, including technology related to a prototype AIDS vaccine, from Centocor. "The $17.3 mil. charge represents the market value of Repligen common stock transferred to Centocor, minus $2.9 mil. in cash paid by Centocor to Repligen," the biotech firm explained. Chart omitted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS012134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel